🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Truly intriguing work from Mayo Myeloma by Dingli et al in Blood Cancer Journal : Does low brain-to-liver uptake on PET-CT (since 🧠 possibly competing against MM cells for glucose) predict outcomes in #MMsm? Yes, especially peri-CAR-T: stronger predictor than visceral EMD!

Our 6-center Spanish CETLAM study of 99 AML pts on VenHMA achieving a morphological response is out in Blood Cancer Journal. Achieving MRD– improved OS (23.3 vs 15.2m, p=0.006) and LFS being the only independent factor in MVA. Thanks to all authors! nature.com/articles/s4140…

Outcomes of older patients (>/= 75) with RRMM treated with teclistamab. No significant difference in CRS, ICANS or ORR #mmsm #bmtsm #Osvolsky Blood Cancer Journal nature.com/articles/s4140…

📢New publication alert!🚨Attrition matters Up to half of #myeloma patients never reach the next LOT 😢 We just published 40 years of RWD in Blood Cancer Journal, showing how much we've improved—and how far we still have to go. Anna de Daniel Hospital Clínic 🔗 doi.org/10.1038/s41408…

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia Blood Cancer Journal nature.com/articles/s4140…

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies | Blood Cancer Journal BCJ. nature.com/articles/s4140…

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period | Blood Cancer Journal nature.com/articles/s4140…

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma. ⁦Mayo Myeloma⁩ ⁦Mayo Clinic Comprehensive Cancer Center⁩ nature.com/articles/s4140…

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations | Blood Cancer Journal nature.com/articles/s4140…

Prognostic value of MRD for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia. AML nature.com/articles/s4140…

My mentor and colleague Mayo Clinic Dr. Ayalew Tefferi will be honored with the Giants of Cancer Care Award OncLive.com tomorrow. #ASCO25 Dr. Tefferi and I work together as Editors of Blood Cancer Journal He is one of the most influential and amazing educators in medicine.

BCJ Editor-in-Chief Dr. Tefferi honored with Giants of Cancer Award

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period | Blood Cancer Journal nature.com/articles/s4140…

Two ways to complex karyotype in MDS—the role of del(5q) and TP53 | Blood Cancer Journal nature.com/articles/s4140…

Tumor progression locus 2, a new potential prognostic factor and therapeutic target in activated B-cell-like diffuse large B-cell lymphoma DLBCL | Blood Cancer Journal nature.com/articles/s4140…

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal nature.com/articles/s4140…

Blood cancer experts to follow. #ASCO25 Vincent Rajkumar Naseema Gangat Sagar Lonial MD marivi mateos Mohamad Mohty John P. Leonard, MD Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Muzaffar Qazilbash Aref Al-Kali Mikkael A. Sekeres MD, MS Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰

Vincent Rajkumar Mayo Clinic OncLive.com Blood Cancer Journal It was an honor to see his journey video in a live audience Vincent Rajkumar. His pioneering work echoed loudly through the planetarium, shining as a star

.Vincent Rajkumar BCJ Editor-in-Chief

My Updated Myeloma Treatment Algorithms. #ASCO25 Bookmark! Presented at COMy. 1) Newly Diagnosed myeloma transplant ineligible.